

PROJECT ECHO®: TELE-MENTORING TO MANAGE IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS RECEIVING CANCER IMMUNOTHERAPIES

Cardiovascular Toxicities with Immune Checkpoint Inhibitors: Recommended references

Guha A, Al-Kindi S, Jain P, Tashtish N, et al. 2020. Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use. *Int J Cancer* 147:1753-1754.

Jain P, Bugarin JG, Guha A, et al. 2021/ Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. *ESMO Open* 6(5) 1-11.

Laenes D, Yu Y, Santens B, et al. 2022. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. *J Clin Oncol* JCO2101808, 2022 Jun 30.

<http://ascopubs.org/doi/full/10.1200/JCO.21.01808>

Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J* 00:1-133.

Naqash AR, Moey MYY, Cherie Tan, XW, et al. 2022. Major adverse cardiac events with immune checkpoint inhibitors: A pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. *J Clin Oncol* <https://doi.org/10.1200/JCO.22.00369>

Nowatzke J, Guedeney P, Palaskas N, et al. 2022 (in press). Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. *Eur J Cancer*.

Sullivan RJ Weber JS. 2022. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. *Nature Reviews: Drug Discovery*. 21:495-508. <https://doi.org/10.1038/s41573-021-00259-5>

Thuny F, Naidoo J, Neilan TG. 2022. Cardiovascular complications of immune checkpoint inhibitors for cancer. *Eur Heart J* 00:1-11. <https://doi.org/10.1093/eurheartj/ehac456>